Sort   by:  
 Page size 
MetabolomicsEmerging mechanisms and promising approaches in pancreatic cancer metabolism.

Pancreatic cancer is an aggressive cancer with a poor prognosis. Metabolic abnormalities are one of the hallmarks of pancreatic cancer, and pancreatic cancer cells can adapt to biosynthesis, energy intake and redox needs through metabolic reprogramming to tolerate nutrient deficiency and hypoxic ...

2025-03-26 | MTBLS12204 | MetaboLights
MetabolomicsELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes described as classical/progenitor and basal-like/squamous PDAC. We hypothesized that integrative transcriptome and metabolome approaches can identify candidate genes whose inactivation contributes to ...
2024-04-02 | MTBLS9418 | MetaboLights
MetabolomicsLimited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors

Nutrient-deprived conditions in the tumor microenvironment (TME) restrain cancer cell viability due to increased free radicals and reduced energy production. In pancreatic cancer cells, a cytosolic metabolic enzyme, wild-type isocitrate dehydrogenase 1 (wtIDH1), enables the adaptation to these co...

2022-04-29 | MTBLS4722 | MetaboLights
MetabolomicsIncreased glucose availability sensitizes pancreatic cancer to chemotherapy
Pancreatic cancer (Pancreatic Ductal Adenocarcinoma; PDAC) is highly resistant to chemotherapy. Effective alternative therapies have yet to emerge, and therefore, chemotherapy remains the best available systematic treatment. The discovery of safe and available adjuncts that can improve chemotherapeu...
2022-10-18 | MTBLS6000 | MetaboLights
MetabolomicsEMT alterations in the solute carrier landscape uncover SLC22A10/A15 imposed vulnerabilities in pancreatic cancer

The involvement of membrane-bound solute carriers (SLCs) in neoplastic transdifferentiation processes is poorly defined. Here, we examined changes in the SLC landscape during epithelial-mesenchymal transition (EMT) of pancreatic cancer cells. We show that two SLCs from the organic anion...

2021-10-15 | MTBLS1925 | MetaboLights
MetabolomicsGut microbiota-derived deoxycholic acid promotes pancreatic regeneration following acute pancreatitis via Reg3a signaling pathway

Recovery from acute pancreatitis (AP) involves complex biological processes, and the mechanisms governing pancreatic repair remain unclear. In a clinical cohort during the recovery phase of AP, impaired pancreatic recovery was associated with intestinal dysbiosis, depletion of the microbial bile ...

2026-03-08 | MTBLS14000 | MetaboLights
MetabolomicsMutations-Upstream-of-Metabolomic-Signature Based Functional Analyses Identify Prognostic Biomarkers and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

Cross-talk among downstream regulatory networks of genome mutations has been the major hypothetical mechanism underlying poor prognosis and low-responsive rates for targeted therapy of pancreatic ductal adenocarcinoma (PDAC). By applying a causal inference-based mutation-upstream-of-the-metabolom...

2025-10-13 | MTBLS13111 | MetaboLights
MetabolomicsHistone serotonylation promotes pancreatic cancer development via lipid metabolism remodeling

Neurotransmitter serotonin (5-hydroxytryptamine [5-HT]) has emerged to play parallel roles in both neurobiology and oncology. Apart from receptor-mediated signaling transduction pattern, serotonin can be covalently integrated into histone (the post-translational modification known as histone sero...

2025-06-13 | MTBLS12569 | MetaboLights
MetabolomicsLow-Protein Diet Enhances Anti-Tumor Immunity in Pancreatic Cancer through Microbiota-Derived Uridine Diphosphate-Galactose
Low-protein diets (LPD) have been linked to improved metabolic health, but their role in pancreatic ductal adenocarcinoma (PDAC) immunotherapy remains unclear. Here we show that an LPD suppresses PDAC progression in male mice by remodeling the gut microbiota and activating anti-tumor immunity. LPD p...
2026-07-09 | MTBLS14989 | MetaboLights
MetabolomicsMutations-Upstream-of-Metabolomic-Signature Based Functional Analyses Identify Prognostic Biomarkers and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

Cross-talk among downstream regulatory networks of genome mutations has been the major hypothetical mechanism underlying poor prognosis and low-responsive rates for targeted therapy of pancreatic ductal adenocarcinoma (PDAC). By applying a causal inference-based mutation-upstream-of-the-metabolom...

2025-10-13 | MTBLS13116 | MetaboLights
Sort   by:  
 Page size